BACKGROUND: Two HPV vaccines prevent infection with HPV-16 and HPV-18, high-risk (cancer-associated) HPV types which together cause approximately 70% of cervical cancers; one vaccine also prevents HPV-6 and HPV-11, which together cause approximately 90% of anogenital warts. Defining type-specific HPV epidemiology in sexually experienced women will help estimate the potential clinical benefits of vaccinating this population. OBJECTIVES: To examine HPV epidemiology in a diverse sample of sexually experienced women, and to determine factors associated with high-risk HPV and vaccine-type HPV (HPV-6, HPV-11, HPV-16 and HPV-18). STUDY DESIGN: Cross-sectional study of 13-26-year-old women (N=409) who completed a questionnaire and provided a cervicovaginal swab. Swabs were genotyped for HPV using PCR amplification. Logistic regression models were used to determine whether participant characteristics, knowledge, and behaviors were associated with high-risk and vaccine-type HPV. RESULTS: Most women (68.4%) were positive for >or=1 HPV type, 59.5% were positive for >or=1 high-risk type, 33.1% were positive for >or=1 vaccine-type HPV, and 3.5% were positive for both HPV-16 and HPV-18: none was positive for all four vaccine types. In adjusted logistic regression models, Black race (OR 2.03, 95% CI 1.21-3.41) and lifetime number of male sexual partners (OR 4.79, 95% CI 2.04-11.23 for >or=10 partner vs. <or=1 partner) were independently associated with high-risk HPV infection. CONCLUSIONS: HPV prevalence was very high in this sample of sexually active young women, but <5% were positive for both HPV-16 and HPV-18, suggesting that vaccination could be beneficial for many individual women who are sexually experienced.
BACKGROUND: Two HPV vaccines prevent infection with HPV-16 and HPV-18, high-risk (cancer-associated) HPV types which together cause approximately 70% of cervical cancers; one vaccine also prevents HPV-6 and HPV-11, which together cause approximately 90% of anogenital warts. Defining type-specific HPV epidemiology in sexually experienced women will help estimate the potential clinical benefits of vaccinating this population. OBJECTIVES: To examine HPV epidemiology in a diverse sample of sexually experienced women, and to determine factors associated with high-risk HPV and vaccine-type HPV (HPV-6, HPV-11, HPV-16 and HPV-18). STUDY DESIGN: Cross-sectional study of 13-26-year-old women (N=409) who completed a questionnaire and provided a cervicovaginal swab. Swabs were genotyped for HPV using PCR amplification. Logistic regression models were used to determine whether participant characteristics, knowledge, and behaviors were associated with high-risk and vaccine-type HPV. RESULTS: Most women (68.4%) were positive for >or=1 HPV type, 59.5% were positive for >or=1 high-risk type, 33.1% were positive for >or=1 vaccine-type HPV, and 3.5% were positive for both HPV-16 and HPV-18: none was positive for all four vaccine types. In adjusted logistic regression models, Black race (OR 2.03, 95% CI 1.21-3.41) and lifetime number of male sexual partners (OR 4.79, 95% CI 2.04-11.23 for >or=10 partner vs. <or=1 partner) were independently associated with high-risk HPV infection. CONCLUSIONS:HPV prevalence was very high in this sample of sexually active young women, but <5% were positive for both HPV-16 and HPV-18, suggesting that vaccination could be beneficial for many individual women who are sexually experienced.
Authors: Anna Koulova; Jennifer Tsui; Kathleen Irwin; Pierre Van Damme; Robin Biellik; Maria Teresa Aguado Journal: Vaccine Date: 2008-12-02 Impact factor: 3.641
Authors: N Krieger; C Quesenberry; T Peng; P Horn-Ross; S Stewart; S Brown; K Swallen; T Guillermo; D Suh; L Alvarez-Martinez; F Ward Journal: Cancer Causes Control Date: 1999-12 Impact factor: 2.506
Authors: Jessica A Kahn; Susan L Rosenthal; Yan Jin; Bin Huang; Azadeh Namakydoust; Gregory D Zimet Journal: Obstet Gynecol Date: 2008-05 Impact factor: 7.661
Authors: Rachel L Winer; Qinghua Feng; James P Hughes; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky Journal: J Infect Dis Date: 2008-01-15 Impact factor: 5.226
Authors: Thomas C Wright; Warner K Huh; Bradley J Monk; Jennifer S Smith; Kevin Ault; Thomas J Herzog Journal: Gynecol Oncol Date: 2008-05 Impact factor: 5.482
Authors: Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy Journal: JAMA Date: 2007-08-15 Impact factor: 56.272
Authors: Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin Journal: Lancet Date: 2007-06-30 Impact factor: 79.321
Authors: J N I Vet; M A de Boer; B E W M van den Akker; B Siregar; S Budiningsih; D Tyasmorowati; S Cornain; A A W Peters; G J Fleuren Journal: Br J Cancer Date: 2008-07-08 Impact factor: 7.640
Authors: Jessica A Kahn; Darron R Brown; Lili Ding; Lea E Widdice; Marcia L Shew; Susan Glynn; David I Bernstein Journal: Pediatrics Date: 2012-07-09 Impact factor: 7.124
Authors: Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Gerald Klinglmair; Renate Pichler; Bettina Zelger; Hasan Serkan Dogan; Tanja Becker; Johannes Esterbauer; Markus Riccabona; Wolfgang Loidl; Wolfgang Horninger; Josef Oswald Journal: World J Urol Date: 2012-12-14 Impact factor: 4.226
Authors: Dana Whittemore; Lili Ding; Lea E Widdice; Darron A Brown; David I Bernstein; Eduardo L Franco; Jessica A Kahn Journal: J Womens Health (Larchmt) Date: 2016-10-18 Impact factor: 2.681
Authors: Jessica A Kahn; Lea E Widdice; Lili Ding; Bin Huang; Darron R Brown; Eduardo L Franco; David I Bernstein Journal: Clin Infect Dis Date: 2016-09-20 Impact factor: 9.079